/
BCAB
$3.83+$0.15 (+4.08%)live
Held · Bookmarked
0 · 0
portfolios · users
Avg position size
—
of holders' portfolios
13F filers
0
institutions
Market cap
$6.1M
2M shares
52-week range
$3.12 – $71.50
1% from low
Sector
BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)
Exchange
NASDAQ
CS
Borrow rate
11.82%
Hard to borrow
Price (6 mo)
Loading chart…
Change$-2183.17
Valuation
Financials
Loading chart…
Click rows below (any statement) to add/remove series. Selection stays as you switch tabs.
| 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $10.6M | $5.2M | $429.0K | $250.0K | $0 | $0 | $11.0M | $2.0M |
| Cost of revenue | $26.3M | $25.9M | $19.9M | $58.3M | $1.2M | $1.2M | $925.0K | $0 |
| Gross profit | −$15.7M | −$20.7M | −$19.5M | −$58.0M | −$1.2M | −$1.2M | $10.1M | $2.0M |
| Gross margin | -147.5% | -398.4% | -4546.4% | -23209.6% | — | — | 91.6% | 100.0% |
| R&D | $26.3M | $25.9M | $19.9M | $58.3M | $79.3M | $103.7M | $63.1M | $43.6M |
| Operating income | −$28.2M | −$28.3M | −$30.1M | −$96.4M | −$108.1M | −$129.7M | −$73.9M | −$59.3M |
| EBITDA | −$27.2M | −$27.4M | −$33.5M | −$94.1M | −$105.3M | −$122.2M | −$68.9M | −$59.2M |
| Net income | −$29.0M | −$29.8M | −$35.9M | −$95.4M | −$105.3M | −$123.5M | −$69.8M | −$59.6M |
| Net margin | -272.7% | -573.0% | -8357.3% | -38160.8% | — | — | -634.3% | -2980.3% |
| EPS (diluted) | -67.00 | -46.50 | -53.00 | -138.00 | -137.00 | -129.00 | -72.00 | -50.50 |
Annual figures · source: Financial Modeling Prep
Analyst estimates (consensus)
| Year | Est. revenue | Est. EPS | EPS range | # Analysts |
|---|---|---|---|---|
| 2026 | $20M | $-46.00 | $-46.00–$-46.00 | 1 |
| 2027 | $4M | $-58.50 | $-58.50–$-58.50 | 1 |
| 2028 | $55M | $-45.00 | $-45.00–$-45.00 | 1 |
| 2029 | $239M | $-48.00 | $-48.00–$-48.00 | 1 |
Forward consensus · source: Financial Modeling Prep
Peer comparison
BioAtla, Inc. Common Stock
BioAtla Inc is a clinical-stage biopharmaceutical company. The company is engaged in the development of a novel class of specific and selective antibody-based therapeutics for the treatment of solid tumor cancer. Its pipeline products comprise mecbotamab vedotin (BA3011), ozuriftamab vedotin (BA3021), and evalstotug (BA3071), and its Phase 1 clinical trial of BA3182 (CAB-EpCAM x CAB-CD3) and Bispecific antibody programs. The company's operations are organized on a single reportable segment, which includes all activities related to the discovery, development, and commercialization of its CAB products.
www.bioatla.com- Employees
- 41
- IPO / List date
- Dec 16, 2020
- HQ
- SAN DIEGO, CA
Held by traders on TradeandTell
No one on the platform currently holds BCAB.
Super investors & insiders
Institutions holding (13F)
No tracked institution reports a position in BCAB as of their last filing.
Insider activity (SEC Form 4)
Stock splits
| Execution date | Ratio |
|---|---|
| 2026-04-06 | 1-for-50reverse |
Recent trades on TradeandTell
No one on the platform has traded BCAB yet.
